drugset / Trial / NCT01188876
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase 1/2
Completed
50 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
Pralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body. Folic acids are used by tumors to increase tumor cell growth and division. It is believed that reducing folic acid will hinder the rapid division of tumor cells, their growth and production. Carboplatin is an FDA approved chemotherapy drug for ovarian, fallopian tube and primary peritoneal cancer. Some antifolate drugs are used with other chemotherapy drugs to enhance cancer-fighting characteristics. It is believed that the study drug pralatrexate may improve the anti-tumor effect of carboplatin. In this research study we are looking for the highest dose of pralatrexate that can be given safely in combination with carboplatin.
Timeline
- Start
- 2010-08
- Primary completion
- 2016-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pralatrexate | Other / unclassified | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Vitamin B12 | Other / unclassified | — | — |
| Background | folic acid | Other / unclassified | — | Oral |